For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving the dynamics of this stable market and offering safe and efficacious choices, especially for orphan subpopulations of the disease like LGS and DS. This report will explore neurologists’ perceptions of established and newly launched AEDs, their prescribing habits in today’s market, and anticipated changes in brand usage as more AEDs expand—and further complicate—prescriber choice.
Questions answered
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: US
Primary research: Survey of 102 neurologists in the United States
Key drugs covered: Keppra, Lamictal, Depakene, Vimpat, Fycompa, Briviact, Xcopri, Epidiolex, Fintepla
Key companies: UCB, Sunovion, Biocodex, SK Biopharmaceuticals, GW Pharmaceuticals, Zogenix, Eisai
Key insights provided: